Thursday, July 9, 2026
🇺🇸 FDA

Drug profile · INN

medroxyprogesterone acetate

MEDROXYPROGESTERONE ACETATE

medroxyprogesterone acetate (MEDROXYPROGESTERONE ACETATE) is a progesterone receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 20
Pipeline programs 18
News articles 0
Drug details — medroxyprogesterone acetate
US status
approved
Class
—
Route
INJECTION
Patents
20
Programs
18
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

medroxyprogesterone acetate (MEDROXYPROGESTERONE ACETATE) is a progesterone receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN medroxyprogesterone acetate
Brand MEDROXYPROGESTERONE ACETATE
Mechanism Progesterone receptor agonist
Target Progesterone receptor
Route INJECTION
Formulation INJECTABLE
Originator Amneal Pharma Europe Ltd

Mechanism of action

Progesterone receptor agonist

Primary target: Progesterone receptor

Approval history

Authority Status Date
FDA approved —

Pipeline programs

Search pipeline Sponsor programs
  1. FLECAINIDE Phase 3 · PARItec · Patent Foramen Ovale Closure Atrial Arrhytmia or Tachycardi
  2. Normal Saline Phase 3 · First People's Hospital · Postoperative Sleep Disturbance
  3. Progesterone Phase 3 · TherapeuticsMD · Secondary Amenorrhea
  4. ASPIRE Phase 2 · George Institute for · Patients with resectable hepatocellular carcinoma (amenable
  5. DR-2021a Phase 2 · Teva Pharma · Amenorrhea
  6. Liposuction Phase 2 · First People's Hospital · Anterior Cruciate Ligament Partial Rupture
  7. Mibavademab Phase 2 · Regeneron UK · Functional Hypothalamic Amenorrhea (FHA)
  8. PBGENE-DMD (IV) Phase 2 · Chongqing Precision Biotech · Duchenne Muscular Dystrophy With Mutations Amenable to PBGEN

Related & competitor drugs

Browse all drugs
  1. desogestrel Progesterone receptor agonist
  2. megestrol acetate Progesterone receptor agonist
  3. norethindrone Progesterone receptor agonist
  4. norethindrone acetate Progesterone receptor agonist
  5. progesterone Progesterone receptor agonist
  6. ulipristal acetate Genito-urinary system and sex hormones (G03)

Related patents

Browse patents Amneal Pharma Europe Ltd patent hub

  1. WO 2026115454

    ANTICORPS ANTI-CLAUDINE 18.2, FRAGMENTS DE LIAISON À L'ANTIGÈNE ET CONJUGUÉS ANTICORPS-MÉDICAMENT ASSOCIÉS ET MÉTHODES D'UTILISATION DANS UNE THÉRAPIE ANTICANCÉREUSE

    Expires Wed May 30 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. WO 2026107136

    CONJUGUÉS ANTICORPS ANTI-CEACAM5-MÉDICAMENT POUR LE TRAITEMENT DU CANCER

    Expires Wed May 16 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. WO 2026052764

    PROCÉDÉ DE NOTATION POUR UNE THÉRAPIE PAR CONJUGUÉ ANTICORPS ANTI-TROP2-MÉDICAMENT

    Expires Wed Mar 07 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. WO 2026042803

    UTILISATION D'UN ANTICORPS BISPÉCIFIQUE ANTI-CLDN4/ANTI-CD137 EN COMBINAISON AVEC UN MÉDICAMENT À BASE DE PLATINE POUR LE TRAITEMENT DU CANCER

    Expires Wed Feb 21 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. WO 2025260285

    CONJUGUÉ ANTICORPS-MÉDICAMENT

    Expires Thu Dec 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. WO 2025262130

    CONJUGUÉ ANTICORPS-MÉDICAMENT

    Expires Thu Dec 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. WO 2025250831

    CONJUGUÉS ANTICORPS-MÉDICAMENT IMMUNOSTIMULANTS À BASE D'AGONISTE DE STING

    Expires Wed Nov 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12403167

    Phenylethanoid glycoside extract from Acanthus ilicifolius L., preparation method thereof and use as anti-liver injury medicament

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. EP 4541380

    STABILE KONZENTRIERTE RADIONUKLID-KOMPLEX-LÖSUNGEN

    Expires Tue Apr 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. WO 2024249235

    CONJUGUÉS ANTICORPS-MÉDICAMENT D'AGENT DE DÉGRADATION DE BET ANTI-CD33 HUMAIN

    Expires Wed Nov 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. WO 2024243450

    MÉTHODES DE TRAITEMENT UTILISANT DES CONJUGUÉS ANTICORPS-MÉDICAMENT ANTI-C-MET

    Expires Wed Nov 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. WO 2024223388

    COMPLEXES CRISTALLINS ENTRE LA VELAGLIFLOZINE ET DES AGENTS DE FORMATION DE CO-CRISTAUX SÉLECTIONNÉS, LEURS PROCÉDÉS DE PRÉPARATION ET LEUR UTILISATION POUR LA PRÉPARATION DE MÉDICAMENTS

    Expires Wed Oct 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. IT 202300006237

    COMPOSIZIONI NUTRACEUTICHE PER IL TRATTAMENTO O PREVENZIONE DI DISORDINI CONNESSI ALLA TRIMETILAMINURIA.

    Expires Sat Oct 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12102688

    Immunomodulatory nanofilaments

    Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. IT 202300001434

    PRODOTTO DI FERMENTAZIONE PER USO NEL TRATTAMENTO DI PATOLOGIE ASSOCIATE ALLA SINDROME METABOLICA E STEATOSI EPATICA.

    Expires Wed Jul 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. IT 202200013882

    PRODOTTO DI FERMENTAZIONE PER IL TRATTAMENTO DI MALATTIE INFIAMMATORIE.

    Expires Wed Dec 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. IT 202200010244

    Lacticaseibacillus paracasei DG® CNCM I-1572 DSM 34154 per uso in un metodo di trattamento della disbiosi in pazienti affetti da IBS

    Expires Thu Nov 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11730741

    6-chromanol derivatives for use as a medicament

    Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. CA 3235923

    PROCEDES DE SYNTHESE A GRANDE ECHELLE DE COMPLEXES DE RADIONUCLEIDES

    Expires Wed Aug 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11701338

    Use of gTso thal in manufacturing medicament for promotion of MS-275 to cross blood-brain barrier

    Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is medroxyprogesterone acetate?

medroxyprogesterone acetate (MEDROXYPROGESTERONE ACETATE) is a progesterone receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for medroxyprogesterone acetate?

MEDROXYPROGESTERONE ACETATE is a marketed brand name for medroxyprogesterone acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of medroxyprogesterone acetate?

medroxyprogesterone acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.